BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 15337539)

  • 1. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
    Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
    Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer.
    Wahlgren T; Nilsson S; Lennernäs B; Brandberg Y
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):662-70. PubMed ID: 17499452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer.
    Galalae RM; Loch T; Riemer B; Rzehak P; Küchler T; Kimmig B; Kovács G
    Strahlenther Onkol; 2004 Sep; 180(9):582-9. PubMed ID: 15378189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life up to six years after (125)I brachytherapy for early-stage prostate cancer.
    Roeloffzen EM; Lips IM; van Gellekom MP; van Roermund J; Frank SJ; Battermann JJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1054-60. PubMed ID: 20097486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
    J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
    Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
    Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
    Lips I; Dehnad H; Kruger AB; van Moorselaar J; van der Heide U; Battermann J; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):656-61. PubMed ID: 17512127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of high dose rate brachytherapy in combination with external beam radiotherapy on men's health-related quality of life and sexual function over a 2 year time span.
    Conaglen HM; de Jong D; Hartopeanu C; Conaglen JV; Tyrie LK
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):197-204. PubMed ID: 23183305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer.
    Hollenbeck BK; Wei JT; Sanda MG; Dunn RL; Sandler HM
    Urology; 2004 May; 63(5):946-50. PubMed ID: 15134986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey.
    Vordermark D; Wulf J; Markert K; Baier K; Kölbl O; Beckmann G; Bratengeier K; Noe M; Schön G; Flentje M
    Acta Oncol; 2006; 45(6):708-16. PubMed ID: 16938814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
    Jo Y; Junichi H; Tomohiro F; Yoshinari I; Masato F
    BJU Int; 2005 Jul; 96(1):43-7. PubMed ID: 15963118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer.
    Fransson P; Damber JE; Widmark A
    Scand J Urol Nephrol; 2009; 43(2):119-26. PubMed ID: 18985545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life of oral cancer patients after low-dose-rate interstitial brachytherapy.
    Yoshimura R; Shibuya H; Miura M; Watanabe H; Ayukawa F; Hayashi K; Toda K
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):772-8. PubMed ID: 18676096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: a prospective assessment of acute and late treatment toxicity.
    Wahlgren T; Nilsson S; Ryberg M; Lennernäs B; Brandberg Y
    Acta Oncol; 2005; 44(6):633-43. PubMed ID: 16165923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.